CEO Dan Schmitt outlines a three-part test for a new drug: it must effectively engage its intended biological target, avoid interacting with other enzymes to prevent toxicity, and be deliverable to a patient in sufficient quantities to be effective. This framework simplifies the core challenges of drug development.
For a difficult-to-treat cancer like metastatic pancreatic cancer, improving survival is paramount. Actuate's drug achieved this, but crucially, it did so while adding minimal toxicity to the standard of care. This focus on patient quality of life is a major differentiator and a key factor for treatment adoption.
Actuate Therapeutics demonstrates a patient-first ethos by having a dedicated group that not only helps patients access their own trials but also guides them to other companies' trials if those are a better fit. This builds community trust and prioritizes patient outcomes over proprietary interests.
After Actuate Therapeutics released positive early trial data for pediatric cancers, leading international research groups initiated contact. They not only wanted to help develop the drug but had already independently tested the molecule, demonstrating how powerful data can attract inbound, high-caliber partnership opportunities.